3-carboxy-4-methyl-5-propyl-2-furanpropionic acid has been researched along with docosapentaenoic acid in 1 studies
| Studies (3-carboxy-4-methyl-5-propyl-2-furanpropionic acid) | Trials (3-carboxy-4-methyl-5-propyl-2-furanpropionic acid) | Recent Studies (post-2010) (3-carboxy-4-methyl-5-propyl-2-furanpropionic acid) | Studies (docosapentaenoic acid) | Trials (docosapentaenoic acid) | Recent Studies (post-2010) (docosapentaenoic acid) |
|---|---|---|---|---|---|
| 100 | 6 | 38 | 417 | 53 | 235 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Callahan, D; Gibson, RA; Guo, XF; Li, D; Liu, G; Sinclair, AJ | 1 |
1 trial(s) available for 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid and docosapentaenoic acid
| Article | Year |
|---|---|
Pure omega 3 polyunsaturated fatty acids (EPA, DPA or DHA) are associated with increased plasma levels of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) in a short-term study in women.
Topics: Adult; Cross-Over Studies; Docosahexaenoic Acids; Double-Blind Method; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Furans; Humans; Propionates | 2020 |